🚀 VC round data is live in beta, check it out!
Precision BioSciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Precision BioSciences and similar public comparables like Oncolytics Biotech, Naturland Holding, Agenus, XSpray Pharma and more.
Precision BioSciences Overview
About Precision BioSciences
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Founded
2006
HQ
Employees
108
Website
Financials (LTM)
EV
$99M
Precision BioSciences Financials
Precision BioSciences reported last 12-month revenue of $30M and negative EBITDA of ($53M).
In the same LTM period, Precision BioSciences generated $30M in gross profit, ($53M) in EBITDA losses, and had net loss of ($51M).
Revenue (LTM)
Precision BioSciences P&L
In the most recent fiscal year, Precision BioSciences reported revenue of $34M and EBITDA of ($42M).
Precision BioSciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $30M | XXX | $34M | XXX | XXX | XXX |
| Gross Profit | $30M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($53M) | XXX | ($42M) | XXX | XXX | XXX |
| EBITDA Margin | (178%) | XXX | (124%) | XXX | XXX | XXX |
| EBIT Margin | (196%) | XXX | (152%) | XXX | XXX | XXX |
| Net Profit | ($51M) | XXX | ($46M) | XXX | XXX | XXX |
| Net Margin | (173%) | XXX | (133%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Precision BioSciences Stock Performance
Precision BioSciences has current market cap of $115M, and enterprise value of $99M.
Market Cap Evolution
Precision BioSciences' stock price is $4.78.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $99M | $115M | 0.0% | XXX | XXX | XXX | $-1.90 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPrecision BioSciences Valuation Multiples
Precision BioSciences trades at 3.3x EV/Revenue multiple, and (1.9x) EV/EBITDA.
EV / Revenue (LTM)
Precision BioSciences Financial Valuation Multiples
As of March 21, 2026, Precision BioSciences has market cap of $115M and EV of $99M.
Equity research analysts estimate Precision BioSciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Precision BioSciences has a P/E ratio of (2.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $115M | XXX | $115M | XXX | XXX | XXX |
| EV (current) | $99M | XXX | $99M | XXX | XXX | XXX |
| EV/Revenue | 3.3x | XXX | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | (1.9x) | XXX | (2.3x) | XXX | XXX | XXX |
| EV/EBIT | (1.7x) | XXX | (1.9x) | XXX | XXX | XXX |
| EV/Gross Profit | 3.3x | XXX | — | XXX | XXX | XXX |
| P/E | (2.2x) | XXX | (2.5x) | XXX | XXX | XXX |
| EV/FCF | (1.8x) | XXX | (1.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Precision BioSciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Precision BioSciences Margins & Growth Rates
Precision BioSciences' revenue in the last 12 month declined by (56%).
Precision BioSciences' revenue per employee in the last FY averaged $0.3M.
Precision BioSciences' rule of 40 is (234%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Precision BioSciences' rule of X is (318%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Precision BioSciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (56%) | XXX | (62%) | XXX | XXX | XXX |
| EBITDA Margin | (178%) | XXX | (124%) | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | 41% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (234%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (318%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 94% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 188% | XXX | 158% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 252% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Precision BioSciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Oncolytics Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Naturland Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Agenus | XXX | XXX | XXX | XXX | XXX | XXX |
| XSpray Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Aardvark Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Precision BioSciences M&A Activity
Precision BioSciences acquired XXX companies to date.
Last acquisition by Precision BioSciences was on XXXXXXXX, XXXXX. Precision BioSciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Precision BioSciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPrecision BioSciences Investment Activity
Precision BioSciences invested in XXX companies to date.
Precision BioSciences made its latest investment on XXXXXXXX, XXXXX. Precision BioSciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Precision BioSciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Precision BioSciences
| When was Precision BioSciences founded? | Precision BioSciences was founded in 2006. |
| Where is Precision BioSciences headquartered? | Precision BioSciences is headquartered in United States. |
| How many employees does Precision BioSciences have? | As of today, Precision BioSciences has over 108 employees. |
| Who is the CEO of Precision BioSciences? | Precision BioSciences' CEO is Michael Amoroso. |
| Is Precision BioSciences publicly listed? | Yes, Precision BioSciences is a public company listed on Nasdaq. |
| What is the stock symbol of Precision BioSciences? | Precision BioSciences trades under DTIL ticker. |
| When did Precision BioSciences go public? | Precision BioSciences went public in 2019. |
| Who are competitors of Precision BioSciences? | Precision BioSciences main competitors are Oncolytics Biotech, Naturland Holding, Agenus, XSpray Pharma. |
| What is the current market cap of Precision BioSciences? | Precision BioSciences' current market cap is $115M. |
| What is the current revenue of Precision BioSciences? | Precision BioSciences' last 12 months revenue is $30M. |
| What is the current revenue growth of Precision BioSciences? | Precision BioSciences revenue growth (NTM/LTM) is (56%). |
| What is the current EV/Revenue multiple of Precision BioSciences? | Current revenue multiple of Precision BioSciences is 3.3x. |
| Is Precision BioSciences profitable? | No, Precision BioSciences is not profitable. |
| What is the current EBITDA of Precision BioSciences? | Precision BioSciences has negative EBITDA and is not profitable. |
| What is Precision BioSciences' EBITDA margin? | Precision BioSciences' last 12 months EBITDA margin is (178%). |
| What is the current EV/EBITDA multiple of Precision BioSciences? | Current EBITDA multiple of Precision BioSciences is (1.9x). |
| What is the current FCF of Precision BioSciences? | Precision BioSciences' last 12 months FCF is ($55M). |
| What is Precision BioSciences' FCF margin? | Precision BioSciences' last 12 months FCF margin is (185%). |
| What is the current EV/FCF multiple of Precision BioSciences? | Current FCF multiple of Precision BioSciences is (1.8x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.